ISHARES BIOTECHNOLOGY ETF (IBB:NASDAQ)
$215.23 -1.17 (-0.5407%)
Analysed ISHARES BIOTECHNOLOGY ETF (IBB:NASDAQ) News Sources
Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus
11-08-2026
247wallst.com
Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips
20-08-2026
247wallst.com
Moderna's 177% Surge Powers a Broad Biotech Rally
20-08-2026
etf.com
Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session
21-08-2026
247wallst.com
The Treasury, the Fed and the threat to your money
21-08-2026
marketwatch.com
2 Biotech Stocks Shaping Up for Major Breakouts
22-08-2026
marketbeat.com
Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling
24-08-2026
yahoo.com
Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips
24-08-2026
247wallst.com
Merck Just Gained 19% in a Month. What Would It Take to Get MRK Stock Up to $200?
25-08-2026
247wallst.com
Moderna Drops 7% Despite a Fresh Wolfe Research Upgrade, BioNTech Slips
26-08-2026
247wallst.com
What is the current price of ISHARES BIOTECHNOLOGY ETF (IBB:NASDAQ)?
The current price of ISHARES BIOTECHNOLOGY ETF (IBB:NASDAQ) is $215.23.
ISHARES BIOTECHNOLOGY ETF (IBB:NASDAQ) absolute price change since previous trading day?
The absolute price change of ISHARES BIOTECHNOLOGY ETF (IBB:NASDAQ) since the previous trading day is $-1.17.
ISHARES BIOTECHNOLOGY ETF (IBB:NASDAQ) percentage price change since previous trading day?
The percentage price change of ISHARES BIOTECHNOLOGY ETF (IBB:NASDAQ) since the previous trading day is -0.5407%.
What is the most recent average sentiment score for ISHARES BIOTECHNOLOGY ETF (IBB:NASDAQ)?
The most recent average sentiment score for ISHARES BIOTECHNOLOGY ETF (IBB:NASDAQ) is 46 out of 100.
What is the most recent average sentiment for ISHARES BIOTECHNOLOGY ETF (IBB:NASDAQ)?
The most recent sentiment for ISHARES BIOTECHNOLOGY ETF (IBB:NASDAQ) is .
SEC-8K** Filing Available For ISHARES BIOTECHNOLOGY ETF (IBB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.